Novel systemic therapy for hepatocellular carcinoma.

Area of Science:

• Hepatobiliary Oncology
• Medical Oncology
• Clinical Trial Design

Background:

• Systemic therapy for advanced hepatocellular carcinoma (HCC) historically relied on multi-kinase inhibitors targeting tumor angiogenesis.
• Recent advancements have introduced molecular targeted therapies and immune checkpoint inhibitors (ICI) as viable treatment options.

Purpose of the Study:

• To review updated clinical trial data for first- and second-line systemic therapy in advanced HCC.
• To discuss key issues including trial design lessons, efficacy-safety balance, and impact on multidisciplinary management.

Main Methods:

• Review of updated clinical trial data for advanced HCC.
• Analysis of trial design, efficacy, safety, and clinical implications.

Main Results:

• Significant expansion of first- and second-line treatment options for advanced HCC.
• Emerging efficacy of immune checkpoint inhibitors (ICI), particularly in combination therapies.
• Combination of ICI targeting the program cell death-1 (PD-1) pathway shows potential for enhanced treatment outcomes.

Conclusions:

• Advanced HCC treatment landscape has evolved with new molecular targeted therapies and ICIs.
• Combination strategies, especially involving PD-1 pathway inhibitors, may improve treatment efficacy.
• Ongoing evaluation of trial design, efficacy, safety, and integration into multidisciplinary care is crucial.